e6vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For
the month of June 2009
Commission File Number 000-28508
Flamel Technologies S.A.
(Translation of registrants name into English)
Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Indicate by check mark whether registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If Yes is marked, indicate below the file number assigned to the registrant in connection
with Rule 12g3-2(b): 82-
INFORMATION FILED WITH THIS REPORT
Document Index
99.1
Press release regarding new feasibility projects and technology
access fee, dated June 22, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Flamel Technologies S.A. |
|
|
|
|
|
|
|
|
|
Dated:
June 22, 2009
|
|
By:
|
|
/s/ Stephen H. Willard
|
|
|
|
|
Name:
|
|
Stephen H. Willard
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press release regarding new feasibility projects and technology
access fee, dated June 22, 2009.
|
exv99w1
Exhibit 99.1
Flamel Technologies Announces New Feasibility Projects;
Technology Access Fee
LYON, France June 22, 2009 Flamel Technologies, SA (Nasdaq: FLML) today announced that it has
entered into agreements with a leading global healthcare provider to assess the applicability of
the Medusa® platform for controlled release formulations of therapeutic proteins. The
Company will receive technology access fees totaling 2.5 million pursuant to these agreements,
plus full development costs for the program. A joint press release regarding the agreement is
anticipated for release in mid July.
Stephen H. Willard, Chief Executive Officer of Flamel Technologies, said: We are very pleased to
add a new partner for multiple molecules using our Medusa technology. We are gratified that our
technology has achieved the recognition which justifies upfront payments as well as the usual
license fees, development fees, milestones, and royalties. We look forward to announcing
additional details of our collaboration in the month to come.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump® is a
controlled release and taste-masking technology for the oral administration of small molecule
drugs. Flamels Medusa® technology is designed to deliver controlled-release
formulations of therapeutic proteins and peptides, as well as small molecule drugs.
Contact:
Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE: + 33 (0) 4 7278-3434
Fax: + 33 (0) 4 7278-3435
Marlio@flamel.com
This document contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including certain plans, expectations, goals and projections
regarding financial results, product developments and technology platforms. All statements that
are not clearly historical in nature are forward-looking, and the words anticipate, assume,
believe, expect, estimate, plan, will, and similar expressions are generally intended to
identify forward-looking statements. All forward-looking statements involve risks, uncertainties
and contingencies, many of which are beyond our control, that could cause actual results to differ
materially from those contemplated in such forward-looking statements. These risks include risks
that products in the development stage may not achieve scientific objectives or milestones or meet
stringent regulatory requirements, uncertainties regarding market acceptance of products in
development, the impact of competitive products and pricing, and the risks associated with Flamels
reliance on outside parties and key strategic alliances. These and other risks are described more
fully in Flamels Annual Report on the Securities and Exchange Commission Form 20-F for the year
ended December 31, 2008. All forward-looking statements included in this release are based on
information available at the time of the release. We undertake no obligation to
update or alter our forward-looking statements as a result of new information, future events or
otherwise.